RefinedPractice
Reminder: Willingness-to-Pay Seminar
5 July 2010
Willingness-to-Pay for a New Pharmaceutical: Is it Worth the Money? Whose Money? During this OHE Lunchtime Seminar, Prof Peter Zweifel, University of Zurich, will discuss the findings…
Biosimilars’ Price Dynamic in Europe
30 June 2010
Europe already has some experience with the impact of biosimilars on pricing, including a price war in Germany for EPOs. Whether that experience will be repeated,…
Price Competition and Biosimilars
23 June 2010
Virtually all models forecast that price competition will be less intense and price declines modest in comparison to the generics model. Many models, however, miss or…
Biosimilars: Modelling the Evolution of the Market
16 June 2010
The OHE model varies from other models of biosimilar markets evolution by starting with transaction prices, rather than list prices, and factoring in the collection of…
Reminder: 2010 Lecture on US Health Reform
14 June 2010
OHE’s 2010 Annual Lecture features Dr Alan Garber, Director both of Stanford University’s Center for Health Policy and its Center for Primary Care and Outcomes Research…
EuroQol Group to Report Key EQ-5D Advances
10 June 2010
The EuroQol Group’s 27th Scientific Plenary will take place in mid-September. Researchers will report on several exciting developments in the EQ-5D, a measure of self-reported health…
Lunchtime Seminar: Willingness-to-Pay
9 June 2010
On 16 July, OHE will present a Lunchtime Seminar by Prof Peter Zweifel, who will discuss his recent research on patients’ willingness to pay for pharmaceuticals.…
Biosimilars and Data Exclusivity
8 June 2010
Data exclusivity is critical to ensuring that biosimilars achieve an appropriate balance between increasing market competition and encouraging innovation. The history of ‘traditional generics’ is a…
News Release: Report on Patient Choice in the UK
4 June 2010
A report published today by The King’s Fund shows that having a choice of hospitals is valued by the majority of patients. However, it is not…